首页 >
法规速递
-
Document: Annex to agenda of the CHMP meeting 26-29 January 2026-2026/1/26
2026-01-27查看详情 > -
Document: Darwin EU study: Clozapine and the incidence of severe neutropenia over time-2026/3/4
2026-03-05查看详情 > -
Page: Scientific Advisory Group on Immune and Inflammatory Diseases-2026/4/1
2026-04-02查看详情 > -
中药保护品种公告（第36号）（2026年第44号）-2026/5/15
2026-05-17查看详情 > -
Regulatory and procedural guideline: ICH guideline Q3C (R8) on impurities: guideline for residual solvents - Step 5-2022/11/28
2022-11-30查看详情 > -
Final Guidance: Nonclinical Evaluation of the Immunotoxic Potential of Pharmaceuticals-2023/6/2
2023-06-05查看详情 > -
国家药监局关于适用《Q13：原料药和制剂的连续制造》国际人用药品注册技术协调会指导原则的公告（2023年第158号）-2023/12/14
2023-12-21查看详情 > -
Document: European Medicines Agency Write PMS API implementation Guide (zip)-2025/1/21
2025-01-22查看详情 > -
Page: Clinical Trials Information System (CTIS): training and support-2025/2/24
2025-02-25查看详情 > -
Document: Start of procedure: Type II variation - extension of indication under evaluation by the CHMP (28 February 2025 - 27 March 2025)-2025/4/1
2025-04-02查看详情 >
